Clinical Assays in Sepsis: Prognosis, Diagnosis, Outcomes, and the Genetic Basis of Sepsis by Vassiliou, Alice Georgia et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Clinical Assays in Sepsis: Prognosis, Diagnosis,
Outcomes, and the Genetic Basis of Sepsis
Alice Georgia Vassiliou, Stylianos E. Orfanos and
Anastasia Kotanidou
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/67985
Abstract
Sepsis is the most widespread medical disorder of the intensive care unit (ICU) and the 
most common cause of death in hospitalized patients. Several endothelium-related mol-
ecules have been investigated as potential biomarkers for early diagnosis and/or progno-
sis of sepsis, providing different results depending on study designs. Therefore, it seems 
that we are still far from the right combination of sepsis markers to be used in clinical 
practice. It is more probable that a panel of diverse biomarkers will be more efficient in 
clinical practice. More recently, the potential use of genetic biomarkers for prognostic 
purposes started emerging for sepsis, in the form of genome-wide association studies. 
The successful use of modern molecular diagnostics could enable rapid identification of 
particularly susceptible or less susceptible individuals, leading to tailored therapeutic 
treatments.
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1. Introduction
Sepsis, as defined by the third consensus definitions for sepsis and septic shock, is a life-
threatening organ dysfunction caused by a dysregulated host response to infection, while 
septic shock is a subset of sepsis with circulatory and cellular/metabolic dysfunction associ-
ated with a higher risk of mortality [1]. However, in the studies used to establish the sepsis-3 
guidelines, patient populations were primarily characterized by the previous definitions of 
sepsis, severe sepsis, and septic shock [2].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Sepsis is the most common medical disorder of the intensive care unit (ICU) and the most fre-
quent cause of death in hospitalized patients; it accounts for 1,000,000 cases and 200,000 deaths 
annually in the United States alone [3]. Unlike other major epidemic illnesses, treatment for 
sepsis is nonspecific. The new surviving sepsis guidelines [4], that provide an update to the 
older guidelines [5, 6], presented statements on early management and resuscitation, limited 
primarily to support organ function and administration of intravenous fluids, antibiotics, and 
oxygen. Sepsis is a syndrome, not a disease [7] and it occurs in patients with infection [8]. 
There are no approved drugs that specifically target sepsis. Drotrecogin alfa (activated pro-
tein C), the only approved drug specifically indicated for the treatment of severe sepsis, was 
withdrawn from the market in 2011 [5, 9].
Hence, in the last several years, the search for prognostic and diagnostic markers of sep-
sis for their use in clinical practice reached its peak. Indeed, the 2001 International Sepsis 
Definitions Conference [2] introduced C-reactive protein (CRP) and procalcitonin (PCT) as 
inflammatory markers in the diagnostic criteria for sepsis. However, the new sepsis-3 defini-
tions [1] recognized that sepsis is a syndrome without as yet a validated standard diagnos-
tic test. Sepsis is recognized to involve early activation of both pro- and anti-inflammatory 
responses [10] along with major modifications in nonimmunologic pathways such as cardio-
vascular, neuronal, autonomic, hormonal, bioenergetic, metabolic, and coagulation [11], all of 
which have prognostic significance. The use of biomarkers for the early diagnosis of sepsis 
may permit early intervention which may reduce the risk of death. Combinations of pro- and 
anti-inflammatory biomarkers in a multimarker testing kit may help identify patients who 
develop severe sepsis before organ dysfunction has advanced too far [12]. Biomarker-guided 
immunotherapy that is administered to patients at the proper immune phase of sepsis may 
potentially be a major advance in the treatment of sepsis.
In the first part of the chapter, the most commonly studied biomarkers of sepsis are reviewed 
for their current uses and diagnostic accuracies, including C-reactive protein, procalcitonin, 
various cytokines and chemokines, endothelial biomarkers, and lactate. The second part of 
the chapter will focus on the genetic markers of sepsis.
2. Sepsis biomarkers
2.1. Pro-inflammatory biomarkers (acute-phase)
2.1.1. C-reactive protein (CRP)
Proteins, such as C-reactive protein and procalcitonin, are synthesized in response to infection 
and inflammation. CRP, named after its ability to precipitate the somatic C-polysaccharide of 
Streptococcus pneumoniae, was the first acute-phase protein to be described and comprises a 
very sensitive systemic marker of inflammation and tissue damage [13]. Currently, CRP is 
used as a clinical marker to assess the presence of infection and can help discriminate bacte-
rial and viral infections [14]. Various studies have shown CRP to be a valuable marker for the 
diagnosis of sepsis [15–19] and disease severity [15, 20]. Besides its use in the diagnosis of 
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 sepsis, CRP has also been evaluated as a prognostic marker. More specifically, in ICU patients, 
elevated concentrations of serum CRP on admission have been associated with increased risk 
of organ failure and mortality [21, 22]. There have been studies, however, that have not been 
able to demonstrate that CRP levels are indicative of survival in septic patients [23, 24].
2.1.2. Procalcitonin (PCT)
PCT is a protein consisting of 116 amino acids with a molecular weight of 13 kDa and is a 
precursor of calcitonin produced by C-cells of the thyroid gland, which is intracellularly 
cleaved by proteolytic enzymes into the active hormone [25]. In 1993 when its elevated level 
was found in patients with bacterial infection, PCT became an important protein in the 
detection and differential diagnosis of inflammatory states [26]. The highest levels of PCT 
are achieved in acute bacterial infections and sepsis. Since then, it has been widely inves-
tigated for its prognostic value in sepsis, and has become the most widely used biomarker 
in the management of infection and sepsis in Europe [27]. The efficacy of serial PCT con-
centrations has been evaluated as a prognostic biomarker of outcome in sepsis [28, 29]. PCT 
clearance has also been extensively studied as a biomarker for monitoring sepsis outcomes; 
at this end various reports have demonstrated significant improvement in PCT clearance 
in survivors compared to nonsurvivors in both severe sepsis and septic shock patients [28, 
30–32]. A large meta-analysis comprising 23 studies with 3944 patients concluded that PCT 
nonclearance was a prognostic factor of death in patients with sepsis [33]. Hence, it has 
been suggested that PCT clearance could be indicative of patient outcome and serial PCT 
concentration measurements throughout hospitalization could facilitate treatment planning 
to improve patient outcome.
Several meta-analyses have investigated the value of PCT as a diagnostic marker of sepsis. 
However, this vast number of studies and meta-analyses has produced conflicting results. 
Uzzan et al. found that PCT represents a good biological diagnostic marker for sepsis, severe 
sepsis, or septic shock and suggested that procalcitonin should be included in diagnostic 
guidelines for sepsis and in clinical practice in intensive care units [34]. The findings of Tang 
et al. on the other hand do not support the widespread use of the procalcitonin test in criti-
cal care settings [35]. Another large meta-analysis consisting of 3244 patients suggested that 
PCT is a helpful biomarker for early diagnosis of sepsis in critically ill patients [36]. As far 
as prognosis is concerned, a meta-analysis of 2353 patients proved that there is a significant 
difference between PCT levels as early as day 1 between survivors and nonsurvivors among 
septic patients [37].
The efficacy of procalcitonin-guided antibiotic treatment has also been studied. A meta-anal-
ysis of 1075 patients concluded that procalcitonin is a helpful method to guide antibiotic ther-
apy and surgical interventions without, however, exhibiting a beneficial effect on mortality 
[38]. The major benefit was shorter antibiotic treatment duration.
In conclusion, PCT in some studies has been found to be a superior marker of infection than 
CRP in critically ill patients, and nonetheless is a useful marker of the severity of infection 
[15, 39–43].




Cytokines are immuno-regulators produced in response to an infection or injury. A more 
clear understanding of the pathophysiological basis of sepsis, including the pro- and anti-
inflammatory response during the hyperinflammatory and immunosuppressive phase of 
the disease, respectively, can lead to an alternative treatment approach. In septic patients, 
secretion of pro-inflammatory cytokines at the systemic inflammatory response syn-
drome or SIRS and anti-inflammatory cytokines, at the compensatory anti-inflammatory 
response syndrome (CARS) [44], occurs in a simultaneous manner from the very first 
instant of infection [45]. Mean serum levels of cytokines are higher in septic compared 
to nonseptic patients. Cytokines have therefore been proposed to be sepsis biomarkers 
in cases of neonatal and adult sepsis [46, 47]. Interleukin-6 (IL-6), IL-8, and IL-10 are the 
most extensively studied cytokines in diagnosing sepsis, evaluating the intensity of the 
inflammatory response and determining the prognosis for the patient. IL-6 comprises 
a pro-inflammatory cytokine, IL-8 is a major chemokine, and IL-10 represents an anti-
inflammatory cytokine.
2.2.1. Pro-inflammatory cytokines and chemokines
Tumor necrosis factor-alpha (TNF-α), IL-1β, and IL-6 are the cytokines that mediate the ini-
tial response of the innate immune system to injury or infection. Neutrophils are the first 
and most important cellular host defense against invading pathogens. Neutrophils migrate 
rapidly from the blood to the site of infection and this recruitment is mediated by pro-inflam-
matory mediators, such as TNF-α, IL-1β, and neutrophil-active chemoattractants, like IL-8. 
Therefore, these cytokines are essentially responsible for the features of SIRS and could be 
potentially useful as biomarkers of sepsis. IL-6 enhances the liver’s production of the so-called 
acute phase reactants, including CRP, and also stimulates a shift in the production of cells in 
the bone marrow so that more polymorphonuclear cells (PMNs) are produced. However, it 
is also possible that the cells entering circulation could disseminate inflammation into other 
organs, eventually leading to damage [48]. Impairment of neutrophil migration has been 
described in sepsis, suggesting that in human sepsis, failure of neutrophil migration is associ-
ated with a poor prognosis. In human sepsis, lipopolysaccharide (LPS) is known to induce 
TNF-α production by activating various kinases, leading to NF κB (nuclear factor kappa light 
chain enhancer of activated B cells) activation.
Levels of circulating cytokines are frequently increased in sepsis [49–57]. IL-6 levels are 
increased in patients with infectious complications and have been used to differentiate SIRS 
from sepsis [58]. Studies have shown that high concentrations of TNF-α and IL-6 are predic-
tive of organ failure and increased mortality in septic patients [55, 57, 59]. IL-8 has been used 
to predict the severity of sepsis in pediatric patients, although the use of IL-8 has not been 
confirmed in adults [60, 61]. A very recent study showed that the interleukin-1 receptor 2 
(IL1R2) might be a better biomarker not only for sepsis diagnosis but also for differentiation 
of sepsis infected with G-positive or G-negative bacteria compared to PCT, Acute Physiology 
and Chronic Health Evaluation II (APACHE II), and CRP [62].
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In line with this, clinical trials with an anti-TNF-α monoclonal antibody in septic patients 
did not show any advantage [63]. Interestingly, it was demonstrated in subsequent studies 
that blocking IL-6 caused a complete inhibition of endotoxin-induced activation of coagula-
tion [64]. Administration of an IL-1 receptor antagonist partly blocked the pro-coagulant 
response in experimental sepsis models and inhibited thrombin generation in patients [65]. 
Overall, anti-TNF-α and IL-1β clinical trials undertaken in patients with sepsis have been 
unsuccessful [66].
2.2.2. IL-27
IL-27, a bioactive member of the IL-12 cytokine family, may serve as a useful biomarker in 
estimating risk of bacterial infection among critically ill pediatric and adult patients [67–70]. 
Moreover, when used in combination with PCT, IL-27 may improve classification of critically 
ill adults with sepsis [68, 71].
2.2.3. Anti-inflammatory cytokines
Just as described above how the pro-inflammatory syndrome is characterized by many dif-
ferent and sometimes redundant cytokines, the CARS response also seems to involve many 
cytokines. The most important, however, is IL-10 [72]. It now has been established that IL-10 
has multiple immunosuppressive roles [73] with its most important being the downregula-
tion of TNF-α. Poor patient outcome has been associated with increased blood levels of the 
anti-inflammatory cytokine IL-10 [74]. IL-10 has been shown to protect endotoxemic mice 
[75–77], whereas in models of polymicrobial sepsis it seems to be deleterious [78, 79]. These 
inconsistent results likely depend on the time of administration and the severity of infection. 
Indeed, in view of these contradicting results, studies have documented that administration 
of anti-IL-10 monoclonal antibodies beyond the initial pro-inflammatory state of polymicro-
bial sepsis improves survival of animals subjected to sepsis [80], and furthermore, it is the tim-
ing and scale of the anti-inflammatory response that predicts severity of infection in murine 
model of sepsis [81].
To summarize, pro- and anti-inflammatory cytokines and chemokines have some value in 
the evaluation of the inflammatory response; however, they lack discriminative power to 
differentiate between infectious and noninfectious systemic inflammation. Elevated lev-
els of pro- and anti-inflammatory cytokines are found mostly in nonsurvivors, whereas 
reduced levels are found in survivors of sepsis [82]. Even though they play an important 
part in the pathogenesis of sepsis, the role of cytokines as sepsis biomarkers remains to be 
established.
2.3. Endothelial proteins as potential biomarkers
Since early widespread endothelial dysfunction and/or damage appear to be directly involved 
in sepsis [83], there is a strong biological rationale for targeting markers of endothelial activa-
tion and dysfunction as biomarkers of the septic syndrome.




Angiopoietin-1 (Ang-1) and angiopoietin-2 are antagonistic factors that trigger endothelial 
cell (EC) activation; the role of angiopoietin-1 is to maintain vessel integrity and block vas-
cular leakage, while angiopoietin-2 (Ang-2) counteracts the protective effects of Ang-1-Tie2 
signaling [84, 85]. Ang-2 has been proposed as a biomarker in sepsis, since its release directly 
reflects vascular barrier breakdown [86–88]. More specifically, Ang-2 levels have been found 
to be elevated in patients with severe sepsis compared to patients with sepsis or not [89–91], 
higher Ang-2 levels have been reported in septic patients with worse clinical outcome [92–
94], and increased Ang-2 levels have been demonstrated in nonsurvivors compared to sur-
vivors [95, 96]. Fewer studies have examined the role of Ang-1 in sepsis; those reports have 
shown either decreased levels of Ang-1 in critically ill patients compared to healthy controls, 
or have associated decreased levels at ICU admission with higher mortality [94, 97].
2.3.2. Selectins
Prior to the firm adhesion of leukocytes to the vascular endothelium and their transmigra-
tion to the sites of injury and inflammation, capture and rolling of leukocytes along the 
endothelium occurs. This is mediated by a family of cell adhesion molecules (or CAMs), 
called the selectin family [98]. Levels of soluble (s)E-selectin are very low in healthy indi-
viduals, whereas increased concentrations have been reported in various inflammatory 
pathologies [99–102]; other investigations have shown higher levels in nonsurvivors than 
survivors [103, 104]. Recently, it was demonstrated that sE-selectin levels may be used as 
predictor of fatal outcome in patients with SIRS [105]. Moreover, sE-selectin has also been 
proposed as a predictor of bacteremia in severe sepsis patients [106]. P-selectin has a similar 
function, but is constitutively expressed in lung ECs, and correlates with lung endothelial 
injury [107]. A recent study by Wang et al. [108] demonstrated in patients hospitalized for 
infections that higher baseline levels of interleukin-6, sE-selectin, and soluble intercellu-
lar adhesion molecule-1 (sICAM-1) may differentiate those patients who will develop a 
mild response to infection from those who will develop full-blown sepsis. A most recent 
study showed that high levels of the circulating endothelial adhesion molecules sE- and 
sP-selectin, measured at ICU admission, appear to be associated with sepsis development 
in time [109].
2.3.3. Soluble intercellular adhesion molecule-1 (sICAM-1)
Both the innate and adaptive immune responses depend on the migration of leukocytes across 
endothelial cells [110]. Specific adhesion glycoproteins are required for the binding of leuko-
cytes to ECs. One such glycoprotein, intercellular adhesion molecule-1 (ICAM-1), controls the 
firm adhesion of neutrophils on endothelium and consequently their transmigration to the 
sites of infection. ICAM-1 has been studied as a biomarker of sepsis severity and outcome. 
These studies have produced inconsistent and conflicting results, possibly reflecting the time 
Sepsis98
point at which they were measured [105]. ICAM-1 production has been shown to be induced 
by endotoxins and has been associated with sepsis severity [102, 111] or mortality [111, 112], 
while sICAM-1 seems to be a reliable biomarker for distinguishing patients with sepsis from 
those with noninfectious SIRS [105].
2.3.4. Soluble platelet/endothelial cell adhesion molecule-1 (sPECAM-1)
Platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) is a 130-kDa cell adhesion 
molecule that is expressed on the surfaces of leukocytes, such as monocytes, neutrophils, and 
some T-cell subsets, as well as on platelets and the intercellular junctions of endothelial cells 
[113]. Serum levels of sPECAM-1 have been demonstrated to be higher in septic patients com-
pared with nonseptic patients at admission and are also higher compared to healthy controls 
[114, 115].
2.3.5. Endocan
Endocan is a proteoglycan expressed and secreted by the vascular endothelium in the lung 
and kidney, in response to pro-inflammatory cytokines and pro-angiogenic factors, which 
inhibits leukocyte migration [116]. The molecule is cleaved through the activity by cathepsin 
G generating a novel endocan peptide fragment of 14 kDa, named p14, which exhibits higher 
concentrations in septic patients compared to healthy volunteers [117]. Several studies have 
shown that this glycoprotein can be used as a strong and significant predictor of sepsis sever-
ity and outcome [118–122].
2.4. Receptor biomarkers
2.4.1. Soluble urokinase-type plasminogen activator receptor (suPAR)
The soluble urokinase-type plasminogen activator receptor (suPAR) was first identified in 
1985 as a cellular binding site for urokinase [123]. Since then suPAR has been investigated 
as a potential prognostic marker in the ICU. In critically ill patients, several studies have 
reported elevated suPAR in SIRS, bacteremia, sepsis, and septic shock, in which high circu-
lating suPAR levels indicated a poor prognosis, including organ dysfunction and mortality 
[124–127].
Systematic reviews have concluded, however, that the diagnostic value of suPAR in sepsis is 
limited [128] and suPAR does not appear to be better in diagnosing sepsis compared to other 
biomarkers, like CRP and PCT [129, 130]. Plasma suPAR levels are, however, a sensitive and 
specific independent prognostic biomarker in patients with bacteremia. This plasma protein 
may be used to identify patients who are severely ill with pneumococcal bacteremia, and 
predict mortality [131–133].
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2.4.2. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1)
Triggering receptor expressed on myeloid cells-1 (TREM-1) is an immunoglobulin whose signal-
ing induces the production of cytokines, chemokines, and reactive oxygen species, all of which 
contribute to the inflammatory response. Furthermore, TREM-1 signaling leads to degranula-
tion of neutrophils and increased phagocytosis. A soluble form of TREM-1 (sTREM-1) can be 
measured in body fluids and has potential as a diagnostic and prognostic biomarker of sep-
sis [134–139]. Other studies, however, have not been able to demonstrate sTREM-1 as a single 
marker sufficient for sepsis diagnosis and prognosis [140–142].
Systematic reviews of the literature have shown that elevated sTREM-1 concentrations have 
a moderate diagnostic performance in differentiating sepsis from SIRS and were not suffi-
cient for sepsis diagnosis in systemic inflammatory patients [140]. Furthermore, it exhibits a 
moderate prognostic significance in assessing the mortality of infection in adult patients and 
sTREM-1 alone is insufficient to predict mortality as a biomarker [142]. However, sTREM-1 
represents a reliable biological marker of bacterial infection [143].
2.4.3. Soluble endothelial protein C receptor (sEPCR)
The protein C (PC) anticoagulant system provides important control of both blood coagu-
lation and inflammatory pathways [144]. This system also involves protein S (PS), and the 
endothelial receptors thrombomodulin (TM) and endothelial protein C receptor (EPCR). 
Conversion of PC to activated PC (APC) is generated by TM-bound thrombin and is dras-
tically augmented by the presence of EPCR [145]. The presence of a soluble form of EPCR 
(sEPCR) that exists under normal conditions and which is elevated in conditions marked by 
enhanced inflammation [146], supports the notion of EPCR shedding. While the role of mem-
brane EPCR is clearly antithrombotic and anti-inflammatory, the physiological significance of 
circulating sEPCR in vivo is as yet not fully understood and it is still unknown whether soluble 
EPCR levels may have a predictive value in the appearance of sepsis.
In previous studies, sEPCR levels in septic patients were found to be significantly higher 
[146, 147], unchanged [148], or even lower [149] than in healthy volunteers. A study by 
Kager et al. [150] showed that increased plasma sEPCR levels correlate with accelerated 
mortality in patients with melioidosis, while overexpression of EPCR in transgenic animals 
aggravates outcome during Gram-negative pneumonia-derived sepsis. In another recent 
report, early kinetics of sEPCR levels in severe sepsis was correlated with outcome [151], 
by a proposed mechanism of counteracting the anticoagulant action of membrane EPCR. 
The authors suggested that sEPCR could provide an early biological marker of outcome in 
severe sepsis. Vassiliou et al. [152] showed that levels of soluble EPCR at ICU admission are 
higher in originally nonseptic patients who subsequently become septic compared to those 
who will not.
2.4.4. Presepsin
Cluster of differentiation 14 (CD14) is a glycoprotein expressed on monocytes and macro-
phages, which serves as a receptor for lipopolysaccharides. As a pattern recognition molecule 
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it plays a role in the innate immune system by activating a pro-inflammatory signaling cas-
cade upon contact with microorganisms [153]. During inflammation, protease activity releases 
soluble CD14 (sCD14) fragments, one of which has been identified as presepsin (sCD14-ST).
Presepsin was discovered as a new marker in Japan in 2002 [154], as a molecule whose levels 
were elevated specifically in the blood of patients with sepsis, and in the last few years has 
been extensively studied as a diagnostic and prognostic sepsis biomarker. In 2012, a multi-
center prospective study investigated the clinical usefulness of presepsin for discriminating 
between bacterial and nonbacterial infections and compared it with PCT and IL-6 [155]. The 
study concluded that presepsin is useful for the diagnosis of sepsis and that it was superior to 
conventional markers and blood cultures. Ulla et al. [153] evaluated the diagnostic and prog-
nostic value of presepsin in the emergency department and found that presepsin was useful 
in the early diagnosis of infection in a population of patients with SIRS, sepsis, severe sepsis, 
and septic shock. Moreover, presepsin exhibited a prognostic value, since its initial levels 
were correlated with mortality. In ICU patients, presepsin demonstrated diagnostic capacity 
in differentiating sepsis severity and prognostic value in mortality [156], while Masson et al. 
[157] found that presepsin measured on the first day in ICU in patients with severe sepsis or 
septic shock was higher in nonsurvivors compared to survivors, thus exhibiting useful prog-
nostic importance. In 2015, three large meta-analyses concluded that presepsin has moderate 
diagnostic capacity for the detection of sepsis and it is an effective adjunct biomarker, but is 
insufficient to detect or rule out sepsis when used alone [158–160].
Since then, more studies have been performed, comparing presepsin to markers such as PCT 
and CRP. Results from these studies have shown that presepsin could differentiate between 
septic and nonseptic patients with comparable accuracy to CRP and PCT [161, 162], while pre-
sepsin and CRP showed similar performance for predicting 28-day mortality [161]. In patients 
with suspected sepsis, presepsin and PCT showed a good diagnostic accuracy in predicting 
bacteremia and bacterial DNAemia, superior to CRP [163]. In two very recent studies, pre-
sepsin seemed to be as valuable a biomarker as PCT or CRP in the evaluation of infectious 
complications in patients after heart transplantation [164], while another study concluded 
that the introduction of presepsin in clinical practice is not justified, since although it is a valu-
able biomarker for diagnosis of infection and sepsis, its diagnostic accuracy does not improve 
that of PCT [165].
Presepsin has been shown to be beneficial as a sepsis marker in adults. Nevertheless, very 
few data are available in neonates. Recent studies have shown that presepsin is significantly 
higher in preterm infants with early onset sepsis (EOS) compared with uninfected infants 
[166] and that it may be used as a reliable and accurate marker for both diagnosis and follow-
up of EOS [167]. Pugni et al. [168] provided reference ranges for presepsin as an effective 
sepsis marker in neonates.
2.5. Lactate
Lactate is currently the most commonly used biomarker to identify sepsis. In the last years, 
several studies have emphasized the prognostic value of initial lactate levels or lactate 
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clearance [169, 170]. Lactate, apart from being the end product of anaerobic glycolysis 
reflecting tissue oxygen delivery-utilization, is also increased during stress and critical 
illness [171]. Elevated serum lactate levels are associated with poor outcomes in diverse 
populations of critically ill patients, such as multiple organ failure, morbidity, and mor-
tality [172–175]. Clinically, serum lactate is a potentially useful biomarker to risk-stratify 
patients with severe sepsis presenting to the emergency department [170, 174, 175], so it 
has been hypothesized that early detection of elevated lactate levels may result in early 
identification of patients at risk of adverse outcomes [176]. In sepsis these elevated levels 
may be due to either impaired lactate clearance or excessive production [177, 178]. Two 
very recent studies [176, 179] utilized serum lactate levels at admission in order to diag-
nose sepsis in undifferentiated patients with suspected sepsis, emphasizing on the util-
ity of early lactate measurement in such context, while Vassiliou et al. demonstrated that 
combining sE- and sP-selectin with serum lactate offers better prognostic value for sepsis 
development in initially nonseptic ICU patients [180].
Lactate kinetics has proved a valuable marker for response to resuscitative handlings in septic 
patients, associated with clinical outcome and mortality. Thus, according to the new sepsis-3 
guidelines “patients with septic shock can be clinically identified by a vasopressor require-
ment to maintain a mean arterial pressure of 65 mmHg or greater and serum lactate level 
greater than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia. This combination is associ-
ated with hospital mortality rates greater than 40%” [1].
2.6. Biomarker panels
Since as yet no single accepted biomarker or combination of biomarkers can be clinically 
used to diagnose patients with suspected sepsis, the multi-marker or panel approach has 
been suggested to improve clinical utility. Many groups have studied such biomarker pan-
els. Kofoed et al. [181] showed that combining data from several markers improves diag-
nostic accuracy in detecting bacterial versus nonbacterial causes of inflammation. Another 
study identified a panel of three different biomarkers that could assess risk of organ dys-
function, shock, and death in emergency department patients with suspected sepsis [182].
Another panel including both pro-inflammatory and anti-inflammatory markers, comprising 
IL-6, IL-8, and the anti-inflammatory cytokine IL-10 was associated with a worse outcome for 
patients with sepsis [183]. As mentioned earlier, high concentrations of TNF-α and IL-6 are 
predictive of organ failure and increased mortality [55, 57], but poor patient outcome is also 
associated with increased levels of the anti-inflammatory cytokine IL-10 [74]. This apparent 
paradox is explained by the proposal that infection induces an initial stage of systemic inflam-
mation (SIRS), with elevated blood levels of pro-inflammatory cytokines (e.g., TNF-α and 
IL-1β), that is followed by a compensatory anti-inflammatory response (CARS) defined by 
high circulating levels of anti-inflammatory cytokines (e.g., IL-10 and IL-13), and it is indeed 
the sustained overproduction of the anti-inflammatory cytokine IL-10 that is the main predic-
tor of severity and fatal outcome [184].
Figure 1 summarizes all major biomarkers involved in the inflammatory response in sepsis.
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Figure 1. Major biomarkers in sepsis. During the inflammatory response a large number of cytokines, chemokines, 
and soluble molecules are secreted, affecting coagulation, endothelial activation and dysfunction, and vascular 
barrier permeability. The result is immune dysregulation and persistent immune suppression. The host immune 
response to sepsis includes activation of both pro- and anti-inflammatory stages and excessive activation of immune 
cells. Proteins, such as CRP and PCT are synthesized in the acute phase in response to infection and inflammation. 
The cells of the innate immune system release large amounts of pro- and anti-inflammatory cytokines, such as 
IL-1β, IL-6, IL-8, TNF-α, and IL-10, during the hyper-inflammatory and immunosuppressive phase of the disease, 
respectively, from the very first instant of infection. The high levels of circulating cytokines can potentiate organ 
damage by endothelial injury and other routes. Ang-2 disrupts the protective effects of Ang-1-Tie2 signaling that 
maintains vessel integrity and inhibits vascular leakage. In critically ill patients, the release of Ang-2 directly reflects 
vascular barrier breakdown. Endothelial damage is associated with activation of neutrophils and expression of 
neutrophil and endothelial adhesion molecules. These molecules help localize leukocytes to the area of injury; 
however, before leaving the blood vessel, inflammatory molecules released by activated neutrophils can produce 
additional endothelial injury. Both the innate and adaptive immune responses depend on the migration of leukocytes 
across endothelial cells. The selectin family, including E-selectin and P-selectin, is an early mediator of the adhesion 
of activated neutrophils to endothelia in inflammatory states, before their firm adhesion and diapedesis at sites of 
tissue injury and inflammation. ICAM-1 controls the firm adhesion of neutrophils on endothelium and consequently 
transendothelial neutrophil migration response to sites of infection. PECAM-1 is a phosphoprotein highly expressed 
on endothelial cells and leukocytes, and comprises an important component in the regulation of neutrophil 
transendothelial migration. Endocan is a proteoglycan expressed and secreted by the vascular endothelium in 
response to pro-inflammatory cytokines and pro-angiogenic factors, and inhibits leukocyte migration. The soluble 
forms of these proteins have been found increased in the sera of septic patients. uPAR is a part of the plasminogen 
activation system, which is involved in tissue reorganization events. The soluble form of uPAR, suPAR, forms 
when UPA binds to uPAR, and its levels are increased in sepsis. TREM-1 is an inflammatory immunoglobulin 
superfamily member, which is expressed in neutrophils, monocytes, and macrophages. TREM-1 triggers and 
expands the inflammatory response, with promoted production of inflammatory mediators, inhibited expression of 
anti-inflammatory mediators, and activated and amplified inflammatory cascade. sTREM-1 is a subtype of secreted 
TREM-1, which has been shown to be released into the blood during infection. The protein C anticoagulant system 
also involves protein S, and the endothelial receptors TM and EPCR. Conversion of protein C to the anticoagulant 
APC is generated by TM-bound thrombin and is drastically augmented by the presence of EPCR. The presence 
of a soluble form of EPCR (sEPCR) is elevated in conditions marked by enhanced inflammation, of unknown 
physiological significance. CD14 is yet another glycoprotein expressed on monocytes and macrophages, and serves 
as a receptor for lipopolysaccharides. As a pattern recognition molecule it plays a role in the innate immune system 
by activating a pro-inflammatory signaling cascade upon contact with microorganisms. During inflammation, 
protease activity releases soluble CD14 (sCD14) fragments, one of which has been identified as presepsin. Other 
pattern recognition receptors involved in immunity are TLRs. Stimulation of TLRs by microbial components 
triggers expression of several genes that are involved in immune responses. Finally, lactate is also increased due 
to production by various tissues through aerobic and anaerobic glycolysis, and from a decreased lactate clearance. 
Ang-1, angiopoietin-1; Ang-2, angiopoietin-2, APC, activated protein C; CD14, cluster of differentiation 14; CRP, 
C-reactive protein; IL, interleukin; PCT, procalcitonin; sEPCR, soluble endothelial protein C receptor; sICAM-1, 
soluble intercellular adhesion molecule-1; sPECAM-1, soluble platelet/endothelial cell adhesion molecule-1; sTREM-
1, soluble triggering receptor expressed on myeloid cells-1; suPAR, soluble urokinase-type plasminogen activator 
receptor; TM, thrombomodulin; TNF-α, tumor necrosis factor-alpha; TLR, Toll-like receptors; UPA, urokinase-type 
plasminogen activator.
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3. Genetic polymorphisms in sepsis
The prospective of genetic biomarkers for prognostic use is well-known for mostly uncom-
mon/rare inherited disorders, but is also emerging for sepsis [185, 186]. Most genes carry 
single-nucleotide polymorphisms (SNPs) at specific exonic or intronic regions.
In order to identify potential markers of susceptibility, severity, and clinical outcome, 
potential markers for survivors and nonsurvivors, and ultimately to identify targets for 
therapeutic intervention, gene polymorphisms have become the most widely used form 
of experimental study. In an attempt to deal with the limitations of these studies, such 
as small sample size and bias in selecting candidate polymorphisms and genes, genome-
wide association studies (GWAS) are now emerging. GWAS concern large, well-conducted, 
multicenter studies that do not involve a prior hypothesis of candidate genes to test for 
association with disease.
3.1. Cell signaling pathways of the innate immune system
3.1.1. Pattern recognition receptors (PRR)
3.1.1.1. Toll-like receptors (TLRs)
Functional characterization of Toll-like receptors (TLRs) has established that innate 
immunity is an adept system that detects invasion of microbial pathogens. Stimulation 
of TLRs by microbial components triggers expression of several genes that are involved 
in immune responses [187]. TLR4 is an essential receptor for Gram-negative enteric LPS 
recognition [188, 189]. The Asp299Gly mutation in human TLR4 impairs LPS signaling 
in homozygous and heterozygous individuals [190], while Smirnova et al. [191] observed 
that rare heterozygous missense mutations of TLR4 contribute to the development of 
systemic meningococcal disease. The D299G allele of the TLR4 gene has also been associ-
ated with increased susceptibility to severe bacterial infections and Gram-negative sepsis 
[192, 193].
3.1.2. Cellular innate immune response
3.1.2.1. IL-8
The 251A/T allele (rs4073) of the IL-8 gene has been studied for its implication in sepsis and 
outcomes. Results until now have shown association of the allele with higher plasma IL-8 
levels, as well as with survival [194]. The A allele has been suggested to be associated with 
protection against sepsis [195], and also with increased risk of sepsis [196]. The heterozygote 
AT genotype has been associated with increased risk of developing severe sepsis [197]. In a 
more recent study, the male population carrying the homozygote TT genotype was found to 
be more susceptible to sepsis, while no association was determined between the 251A/T allele 
and IL-8 serum levels in septic patients [198].
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3.2. Adaptive immune response
3.2.1. Cytokines
3.2.1.1. Tumor necrosis factor-α promoter polymorphisms
Initially, the G-to-A polymorphism at position 308nt in the promoter region of the TNF-α 
gene was found to be associated with adverse outcome in patients with severe sepsis and 
septic shock [199, 200]. A large meta-analysis [201] concluded that the polymorphism is 
associated with sepsis, but is not associated with sepsis mortality. However, several stud-
ies later were not able to show association of TNF-α-308 SNP and development of sepsis 
[202, 203].
3.2.1.2. IL-6 polymorphisms
A key inflammatory cytokine that has been examined in genetic association studies in infec-
tious diseases is , producing also conflicting results. First of all, studies on the C allele of 
the G/C polymorphism at position 174nt of the IL-6 gene have shown its association with 
both high and low plasma IL-6 levels [204, 205], or even no association at all [206]. One 
study in critically ill patients did not find association between the 174 G/C polymorphism 
and sepsis appearance, but associated the polymorphism with improved survival rates in 
patients with sepsis [207]. A different study reported that the same polymorphism was not 
associated with survival [208]. A meta-analysis on the position 174nt polymorphism and 
the risk of sepsis in very low birth weight infants concluded that the available data are not 
consistent with more than a modest association between the IL-6 polymorphism and neo-
natal sepsis [209].
3.3. Systemic effectors of inflammation and coagulation
3.3.1. Angiotensin-converting enzyme (ACE)
Studies have compared the effects of the angiotensin-converting enzyme (ACE) inser-
tion/deletion (I/D) polymorphisms on the incidence and outcome of sepsis and acute 
respiratory distress syndrome (ARDS). In ventilated low birth weight infants the ACE 
insertion/deletion (I/D) polymorphism does not have a significant effect on the incidence 
or outcome of sepsis [210, 211]. Studies and meta-analyses showed that carriers of I allele 
(D/I genotype and I/I genotype) were at increased sepsis risk [212–214], but the poly-
morphism is not associated with outcome in critically ill septic patients [214, 215]. With 
regard to ARDS, the data of Villar et al. [216] do not support an association of the ACE 
gene I/D polymorphism with susceptibility or mortality in severe sepsis or with sepsis-
induced ARDS in Spanish patients, but Cardinal-Fernandez et al. demonstrated that the 
presence of the allele D of the ACE gene is associated with ARDS in patients with severe 
sepsis [217].
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3.3.2. Endothelial protein C receptor (EPCR)
A few studies have compared the effects of the EPCR haplotypes on the incidence and out-
come of sepsis. Two studies have shown that EPCR mutations and polymorphisms influ-
ence the risk of severe sepsis in children and adults [218, 219]. More specifically, the rare 
23-bp insertion is significantly more common among patients with severe sepsis [218], while 
simultaneous carriers of minor alleles belonging to both the H1 and H3 haplotypes may be at 
reduced risk of developing severe sepsis and/or septic shock among critically ill patients [219].
Table 1 lists the role of major circulating biomarkers and genetic polymorphisms in the prog-
nosis and diagnosis of sepsis.
Biomarker Diagnostic significance Prognostic significance
C-reactive protein (CRP) - Discriminates bacterial and viral 
infections [14]
- CRP is a valuable marker for the 
disease severity [15, 20]
- Measurement of CRP is an indicator  
of sepsis [15–19]
- Elevated concentrations of serum 
CRP on admission have been 
associated with increased risk of 
organ failure and mortality [21, 22]
Procalcitonin (PCT) - PCT is important in the detection and 
differential diagnosis of inflammatory 
states [26]. The highest levels of PCT  
are achieved in acute bacterial 
infections and sepsis
- PCT nonclearance is a prognostic 
factor of death in patients with sepsis 
[33]
- PCT is a good biological diagnostic 
marker for sepsis, severe sepsis, or 
septic shock [34]
- Significant difference between PCT 
levels as early as day 1 between 
survivors and nonsurvivors among 
septic patients [37]
- PCT is a helpful biomarker for early 
diagnosis of sepsis in critically ill 
patients [36]
- Serial PCT concentrations may have 
value in monitoring sepsis outcomes 
[28, 29]
Tumor necrosis factor-α (TNF-α) - Levels of TNF-α are frequently 
increased in sepsis [49, 56]
- High concentrations of TNF-α 
are predictive of organ failure and 
increased mortality in septic patients 
[55]
Interleukin-1β (IL-1β) - Levels of IL-1β are frequently 
increased in sepsis [56]
Interleukin-6 (IL-6) - Levels of IL-6 are frequently increased 
in sepsis [50, 54, 56]
- High concentrations of IL-6 are 
predictive of organ failure and 
increased mortality in septic patients 
[57, 59]
- IL-6 levels are increased in patients 
with infectious complications and have 
been used to differentiate systemic 
inflammatory response syndrome 
(SIRS) from sepsis [58]
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Biomarker Diagnostic significance Prognostic significance
Interleukin-8 (IL-8) - Levels of IL-8 are frequently increased 
in sepsis [50, 56]
- IL-8 has been used to predict 
the severity of sepsis in pediatric 
patients, although the use of IL-8 has 
not been confirmed in adults [60, 61]
Interleukin-27 (IL-27) - Useful biomarker in estimating risk  
of bacterial infection among critically  
ill pediatric and adult patients [67–70]
- In combination with PCT, IL-27 may 
improve classification of critically ill 
adults with sepsis [68, 71]
Interleukin-10 (IL-10) - Poor patient outcome has been 
associated with increased blood 
levels of the anti-inflammatory 
cytokine IL-10 [74]
Angiopoietin-1 (Ang-1) - Decreased levels in critically ill septic 
or nonseptic patients compared to 
healthy controls [94]
- Decreased levels of Ang-1 at ICU 
admission are correlated with higher 
mortality [97]
Angiopoietin-2 (Ang-2) - Ang-2 levels are higher in patients 
with severe sepsis compared to patients 
with or without SIRS or sepsis [89–91]
- Increased Ang-2 plasma levels have 
been associated with worst clinical 
outcome in patients with major trauma 
and severe sepsis or shock [92–94]
- Increased Ang-2 plasma in 
nonsurvivors compared to survivors 
[95, 96]
Selectins - Soluble E-selectin concentration 
increases in various inflammatory 
pathologies [99–102]
- Higher sE-selectin levels in 
nonsurvivors than survivors [103, 
104]
- sE-selectin levels may be used as 
predictor of fatal outcome in patients 
with SIRS [105]
- sE-selectin has also been proposed 
as a predictor of bacteremia in severe 
sepsis patients [106]
High levels of sE- and sP-selectin at 
ICU admission, are associated with 
sepsis development in time [109]
Soluble in tercellular adhesion 
molecule-1 (sICAM-1)
-s ICAM-1 production has been shown 
to be related to increased sepsis severity 
[102, 111]
- sICAM-1 concentration has been 
shown to be related to increased 
mortality [111, 112]
- sICAM-1 appears to be a reliable 
biomarker for classifying patients with 
infectious SIRS, i.e., sepsis, from those 
with noninfectious SIRS [105]
Soluble platelet/endothelial cell 
adhesion molecule-1 (sPECAM-1)
- sPECAM-1 is higher at admission in 
septic patients compared with nonseptic 
patients and healthy controls [114, 115]
Endocan - Exhibits higher concentrations in 
septic patients compared to healthy 
volunteers [117]
- A strong and significant predictor 
of sepsis severity and outcome 
[118–122]
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Biomarker Diagnostic significance Prognostic significance
Soluble urokinase-type 
plasminogen activator receptor 
(suPAR)
- Elevated suPAR in conditions of SIRS, 
bacteremia, sepsis, and septic shock 
[124–127]
- High circulating suPAR levels 
indicate an unfavorable prognosis, 
including organ dysfunction and 
mortality [124–127]
- Diagnostic value of suPAR for 
identifying sepsis is limited [128]
- In patients with bacteremia, suPAR 
may be used to identify severely ill 
patients and predict mortality [131, 133]
Soluble triggering receptor 
expressed on myeloid cells-1 
(sTREM-1)
- Moderate diagnostic performance in 
differentiating sepsis from SIRS [140]
- Moderate prognostic significance in 
assessing the mortality of infection in 
adult patients and sTREM-1 alone is 
insufficient to predict mortality as a 
biomarker [142]
- sTREM-1 represents a reliable biological 
marker of bacterial infection [143]
Soluble endothelial protein C 
receptor (sEPCR)
- sEPCR levels in septic patients have 
been found to be significantly higher 
[146, 147], unchanged [148], or lower 
[149] than in healthy volunteers
- sEPCR levels correlated with worst 
outcomes; has been suggested that 
it may act as a biological marker of 
outcome in severe sepsis [150–152]
- Levels of sEPCR at ICU admission 
are higher in originally nonseptic 
patients who subsequently become 
septic compared to those who will 
not [152]
Presepsin - Discriminates between bacterial and 
nonbacterial infections [155]
- Initial values significantly 
correlated with in-hospital mortality 
of patients affected by sepsis, severe 
sepsis, or septic shock [156]
- Early diagnosis of infection in a 
population of patients with SIRS, sepsis, 
severe sepsis, and septic shock [153]
- Presepsin reveals prognostic value 
with respect to 30 days and 6 months 
all-cause mortality throughout the 
first week of ICU treatment [153]
- In patients with suspected severe 
sepsis and septic shock, presepsin 
reveals valuable diagnostic capacity to 
differentiate sepsis severity [156]
- Presepsin measured on the first 
day in ICU in patients with severe 
sepsis or septic shock was higher in 
nonsurvivors compared to survivors 
[157]
- Presepsin can differentiate between 
septic and nonseptic patients with 
comparable accuracy to CRP and PCT 
[161, 162]
Lactate - Elevated serum lactate levels in  
sepsis [177, 178]
- Elevated serum lactate levels are 
associated with poor outcomes in 
diverse populations of critically ill 
patients, such as multiple organ failure, 
morbidity, and mortality [172–175]
- Early serum lactate levels can 
diagnose sepsis in undifferentiated 
patients with suspected sepsis [176, 179]
- Serum lactate is a potentially useful 
biomarker to risk-stratify patients 
with severe sepsis presenting to the 
emergency department [170, 174, 175]
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Biomarker Diagnostic significance Prognostic significance
- Combining sE- and sP-selectin with 
serum lactate offers better prognostic 
value for sepsis development in 
initially nonseptic ICU patients [180]
Genetic polymorphisms - Distinguish patients with sepsis  
from patients with sterile inflammation
- Predict long-term outcomes and 
identify patients who will be at 
risk for developing adverse clinical 
outcomes
Toll-like receptors (TLRs) - D299G allele of TLR4 gene 
associated with increased 
susceptibility to severe bacterial 
infections and Gram-negative sepsis 
[192, 193]
IL-8 - The 251A/T allele has been 
associated with survival [194], 
protection against sepsis [195], and 
also increased risk of sepsis [196]
- The heterozygote AT genotype has 
been associated with increased risk 
of developing sepsis [197]
- Male T allele carriers are more 
susceptible to sepsis [198]
TNF-α - G-to-A polymorphism associated  
with sepsis [201]
- G-to-A polymorphism associated 
with adverse outcomes in patients 
with severe sepsis and septic shock 
[199, 200]
- No association of G-to-A 
polymorphism and development of 
sepsis [202, 203]
- G-to-A polymorphism not 
associated with sepsis mortality [201]
IL-6 - 174 G/C polymorphism showed  
modest association with neonatal sepsis 
[209]
- 174 G/C polymorphism was 
associated with improved survival 
rates in patients with sepsis [207]
- 174 G/C polymorphism was not 




- Insertion/deletion (I/D) 
polymorphism does not have an 
effect on the incidence or outcome of 
sepsis in ventilated low birth infants 
[210, 211]
- Carriers of the I allele at increased 
sepsis risk [212–214]
- I polymorphism not associated 
with outcome in critically ill septic 
patients [214–216]
- The presence of the D allele is 
associated with ARDS in patients 
with severe sepsis [217]
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4. Conclusion
Unfortunately, a lot of work remains to find the right combination of markers to be used in 
clinical practice. Some have been effective in reducing mortality, but their use in diagnosis 
and prognosis of sepsis has been limited. It seems that a panel of diverse biomarkers rather 
than a group of two or three related biomarkers will be more efficient in clinical practice.
Genome-wide association studies may help confirm current findings and make them clini-
cally applicable. Hence, developing high-throughput approaches for the analysis of alterna-
tive mechanisms by which SNPs can cause disease will be one of the remaining challenges for 
genomic research. Hopefully, the findings that will be generated will facilitate the successful 
use of modern molecular diagnostics and could enable rapid identification of particularly 
susceptible or less susceptible individuals, leading to tailored therapeutic approaches.
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Biomarker Diagnostic significance Prognostic significance
Endothelial protein C receptor 
(EPCR)
- The rare 23-bp insertion is significantly 
more common among patients with 
severe sepsis [218]
- Influences the risk of severe sepsis 
in children and adults [218, 219]
- Simultaneous carriers of minor 
alleles belonging to both the H1 and 
H3 haplotypes may be at reduced 
risk of developing severe sepsis and/
or septic shock among critically ill 
patients [219]
Table 1. Role of major circulating biomarkers and genetic polymorphisms in sepsis. Please note that the protein names 
are capitalized, whereas gene names are capitalized and italicized.
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